Literature DB >> 31461601

Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R.

Nadine Lübke1, Björn Jensen1, Falk Hüttig1, Torsten Feldt1, Andreas Walker1, Alexander Thielen2, Martin Däumer2, Martin Obermeier3, Rolf Kaiser4, Elena Knops4, Eva Heger4, Saleta Sierra4, Mark Oette5, Thomas Lengauer6, Jörg Timm7, Dieter Häussinger7.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31461601     DOI: 10.1056/NEJMc1806554

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

1.  Retroviral integrase: Structure, mechanism, and inhibition.

Authors:  Dario Oliveira Passos; Min Li; Robert Craigie; Dmitry Lyumkis
Journal:  Enzymes       Date:  2021-08-23

2.  Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy.

Authors:  Kairoonisha Mahomed; Carole L Wallis; Liezl Dunn; Shavani Maharaj; Gary Maartens; Graeme Meintjes
Journal:  South Afr J HIV Med       Date:  2020-07-02       Impact factor: 2.744

3.  Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.

Authors:  Dominique L Braun; Thomas Scheier; Ulrich Ledermann; Markus Flepp; Karin J Metzner; Jürg Böni; Huldrych F Günthard
Journal:  Viruses       Date:  2020-11-19       Impact factor: 5.048

Review 4.  Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.

Authors:  Steven J Smith; Xue Zhi Zhao; Dario Oliveira Passos; Dmitry Lyumkis; Terrence R Burke; Stephen H Hughes
Journal:  Viruses       Date:  2021-01-29       Impact factor: 5.048

5.  Altered HIV-1 mRNA Splicing Due to Drug-Resistance-Associated Mutations in Exon 2/2b.

Authors:  Lisa Müller; Wiebke Moskorz; Anna-Lena Brillen; Frank Hillebrand; Philipp Niklas Ostermann; Niklas Kiel; Lara Walotka; Johannes Ptok; Jörg Timm; Nadine Lübke; Heiner Schaal
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

6.  Exploring the mechanisms behind HIV drug resistance in sub-Saharan Africa: conceptual mapping of a complex adaptive system based on multi-disciplinary expert insights.

Authors:  Anneleen Kiekens; Bernadette Dierckx de Casterlé; Giampietro Pellizzer; Idda H Mosha; Fausta Mosha; Tobias F Rinke de Wit; Raphael Z Sangeda; Alessio Surian; Nico Vandaele; Liesbet Vranken; Japhet Killewo; Michael Jordan; Anne-Mieke Vandamme
Journal:  BMC Public Health       Date:  2022-03-07       Impact factor: 3.295

7.  Antiretroviral Imprints and Genomic Plasticity of HIV-1 pol in Non-clade B: Implications for Treatment.

Authors:  Jude S Bimela; Aubin J Nanfack; Pengpeng Yang; Shaoxing Dai; Xiang-Peng Kong; Judith N Torimiro; Ralf Duerr
Journal:  Front Microbiol       Date:  2022-02-09       Impact factor: 5.640

8.  Occurrence of the S230R integrase strand inhibitor mutation in a treatment-naïve individual case report.

Authors:  Smitha Gudipati; Indira Brar; Alicia Golembieski; Zachary Hanna; Norman Markowitz
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

9.  SARS-CoV-2 Evolution and Spike-Specific CD4+ T-Cell Response in Persistent COVID-19 with Severe HIV Immune Suppression.

Authors:  Hortensia Álvarez; Ezequiel Ruiz-Mateos; Pedro Miguel Juiz-González; Joana Vitallé; Irene Viéitez; María Del Carmen Vázquez-Friol; Isabel Torres-Beceiro; Alberto Pérez-Gómez; Pilar Gallego-García; Nuria Estévez-Gómez; Loretta De Chiara; Eva Poveda; David Posada; Josep M Llibre
Journal:  Microorganisms       Date:  2022-01-11

10.  Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.

Authors:  Mark Underwood; Joe Horton; Keith Nangle; Judy Hopking; Kimberly Smith; Michael Aboud; Brian Wynne; Jörg Sievers; Eugene L Stewart; Ruolan Wang
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.